Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index; 31 of the 64 sources its claims cite were checked for support.

Tet-On Systems For Doxycycline-inducible Gene Expression

Open access
T. Das, Atze, Tenenbaum, Liliane, Berkhout, Ben · 2016 · Current Gene Therapy

Abstract

The tetracycline-controlled Tet-Off and Tet-On gene expression systems are used to regulate the activity of genes in eukaryotic cells in diverse settings, varying from basic biological research to biotechnology and gene therapy applications. These systems are based on regulatory elements that control the activity of the tetracycline-resistance operon in bacteria. The Tet-Off system allows silencing of gene expression by administration of tetracycline (Tc) or tetracycline-derivatives like doxycycline (dox), whereas the Tet-On system allows activation of gene expression by dox. Since the initial design and construction of the original Tet-system, these bacterium-derived systems have been significantly improved for their function in eukaryotic cells. We here review how a dox-controlled HIV-1 variant was designed and used to greatly improve the activity and dox-sensitivity of the rtTA transcriptional activator component of the Tet-On system. These optimized rtTA variants require less dox for activation, which will reduce side effects and allow gene control in tissues where a relatively low dox level can be reached, such as the brain.

Overview

CoChat Summary

TL;DR

This review describes how a doxycycline-controlled HIV-1 variant was used to evolve and improve the rtTA component of the Tet-On system, yielding rtTA variants with greater activity and dox sensitivity. It compares optimized variants (M2, V10, V16) and discusses when each is preferable in vitro and in vivo.

Key findings

  • Viral evolution of HIV-rtTA selected tetO-LTR deletions (6 of 8 tetO elements deleted, plus a 14–15 nt spacer deletion) and rtTA mutations including F86Y; F86Y increased transcriptional activity and dox sensitivity without affecting background activity, whereas A209T had no effect.
  • rtTA3 (S12G+F86Y+A209T) was 5-fold more active at high dox and required 25-fold less dox than rtTA2S-S2; V16 was 7-fold more active at high dox and 100-fold more sensitive than rtTA2S-S2, with no activity without dox in integrated pTet-reporter assays.
  • In transient transfection, V16 had highest dox-induced activity but low detectable background; V10 had no background and superior fold-induction, making V10 optimal for most transient/episomal applications, while V16 is preferred when high activity at low dox is needed.
  • In stably transduced cells, V16 showed highest dox-induced activity, fold-induction, and reactivation after dox withdrawal; V16 outperformed M2 for AAV-delivered GDNF in rat brain at clinically-approved sub-antimicrobial dox doses.

Methods

  • Narrative review of Tet-Off/Tet-On systems, focusing on optimization of rtTA via a dox-controlled HIV-1 variant (HIV-rtTA) and comparison of rtTA variants.
  • Data/sample: synthesis of referenced in vitro, ex vivo, animal, and clinical/preclinical studies; includes comparison of M2, V10, and V16 in transiently transfected and lentivirally transduced cells.
  • Main analysis: qualitative synthesis and comparison of dox sensitivity, activity, background, fold-induction, and in vivo applicability; no new primary experimental methods are reported for the review itself.

Limitations

  • Stated: direct comparison of new Tet-On systems was limited to in vitro cell culture; optimal rtTA for complex in vivo situations is unknown and may depend on cell/tissue type.
  • Stated: in vivo use can be complicated by immune responses against rtTA in rodents and non-human primates, and toxic side effects of tTA/rtTA in transgenic mice; more dox-sensitive rtTA like V16 may show prolonged activity after dox withdrawal.
  • Stated: whether S12G and V9I DBD mutations affect rtTA interaction with cellular promoter regions and cellular gene expression remains to be determined. Evident: as a review, it relies on prior studies and includes some unpublished data, so conclusions about variant superiority are context-dependent.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2174/1566523216666160524144041

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. (1) Tc-controlled regulation of gene expression. (A) Tn10 tet operon. In E. coli, TetR binds as a dimer to the tetO1 and tetO2 sites in the Tn10 tet operon. This interaction blocks the activity of the underlying promoters (PA, PR1 and PR2) and inhibits transcription of the tetA and tetR genes. Binding of Tc or dox triggers a conformational switch in TetR that prevents tetO binding and results in the activation of TetA and TetR production. (B) The Tet-Off system. Fusion of TetR to the activation domain of the herpes simplex virus VP16 protein (VP16 AD) resulted in the Tc-controlled transcriptional activator (tTA). Binding of tTA to the Ptet promoter that consists of 7 tetO sequences fused to a minimal TATA-box containing eukaryotic promoter, activates expression of the downstream positioned gene-of-interest (G.O.I.) Binding of Tc or dox induces a conformational change in the TetR domain of tTA, which prevents tetO binding and switches gene expression off. (C) The Tet-On system. The reverse-tTA (rtTA) variant exhibits a reverse phenotype and does not bind tetO in the absence of an effector. Binding of dox triggers a conformational switch in rtTA, which allows tetO binding. Subsequent activation of the Ptet promoter drives expression of the downstream positioned gene. The initial version of rtTA had a low affinity for Tc and was not activated by this compound.
Fig. (1) Tc-controlled regulation of gene expression. (A) Tn10 tet operon. In E. coli, TetR binds as a dimer to the tetO1 and tetO2 sites in the Tn10 tet operon. This interaction blocks the activity of the underlying promoters (PA, PR1 and PR2) and inhibits transcription of the tetA and tetR genes. Binding of Tc or dox triggers a conformational switch in TetR that prevents tetO binding and results in the activation of TetA and TetR production. (B) The Tet-Off system. Fusion of TetR to the activation domain of the herpes simplex virus VP16 protein (VP16 AD) resulted in the Tc-controlled transcriptional activator (tTA). Binding of tTA to the Ptet promoter that consists of 7 tetO sequences fused to a minimal TATA-box containing eukaryotic promoter, activates expression of the downstream positioned gene-of-interest (G.O.I.) Binding of Tc or dox induces a conformational change in the TetR domain of tTA, which prevents tetO binding and switches gene expression off. (C) The Tet-On system. The reverse-tTA (rtTA) variant exhibits a reverse phenotype and does not bind tetO in the absence of an effector. Binding of dox triggers a conformational switch in rtTA, which allows tetO binding. Subsequent activation of the Ptet promoter drives expression of the downstream positioned gene. The initial version of rtTA had a low affinity for Tc and was not activated by this compound.CC BY-NC · PubMed Central
Fig. (2) Construction and optimization of the Tet-On system. (A) Schematic overview of the development of rtTA variants by rational design, random mutation and screening in E. coli and yeast (S. cerevisiae) and virus evolution in human cells. See text for details. The color of the TetR domain reflects the effector responsiveness (white, low Tc/dox response; black, high Tc/dox response). (B) Mutations in the TetR moiety and activation domain (AD) in different rtTA variants. The activity of the variants indicated with an arrow was directly compared in transiently transfected and stably transduced cells (Figs. 5, 6).
Fig. (2) Construction and optimization of the Tet-On system. (A) Schematic overview of the development of rtTA variants by rational design, random mutation and screening in E. coli and yeast (S. cerevisiae) and virus evolution in human cells. See text for details. The color of the TetR domain reflects the effector responsiveness (white, low Tc/dox response; black, high Tc/dox response). (B) Mutations in the TetR moiety and activation domain (AD) in different rtTA variants. The activity of the variants indicated with an arrow was directly compared in transiently transfected and stably transduced cells (Figs. 5, 6).CC BY-NC · PubMed Central
Fig. (3) The dox-dependent HIV-rtTA virus. (A) Transcription of wild-type HIV-1 is activated by the binding of the viral Tat protein to the TAR hairpin structure that is present at the 5’ end of nascent RNA transcripts. This Tat-TAR axis thus controls viral gene expression and replication. (B) In HIV-rtTA, Tat and TAR are inactivated by mutation and functionally replaced by the rtTA-tetO components of the Tet-On system, by insertion of the rtTA gene at the site of the nef gene and insertion of tetO sequences in the LTR-promoter region. Transcription of this HIV-1 variant is activated by the binding of rtTA to the tetO-LTR promoter. Because rtTA binds the tetO sites exclusively in the presence of dox, HIV-rtTA does not replicate in the absence of this effector. (C) Dox-controlled replication of HIV-rtTA strains with the original rtTA-2S-S2 gene (left panel) and the F86Y-mutated variant (right panel) in SupT1 T-cells at different dox-concentrations. Virus replication is monitored by measuring the viral capsid protein (CA-p24) in the culture supernatant. Reproduced from [67] (© 2004, the American Society for Biochemistry and Molecular Biology).
Fig. (3) The dox-dependent HIV-rtTA virus. (A) Transcription of wild-type HIV-1 is activated by the binding of the viral Tat protein to the TAR hairpin structure that is present at the 5’ end of nascent RNA transcripts. This Tat-TAR axis thus controls viral gene expression and replication. (B) In HIV-rtTA, Tat and TAR are inactivated by mutation and functionally replaced by the rtTA-tetO components of the Tet-On system, by insertion of the rtTA gene at the site of the nef gene and insertion of tetO sequences in the LTR-promoter region. Transcription of this HIV-1 variant is activated by the binding of rtTA to the tetO-LTR promoter. Because rtTA binds the tetO sites exclusively in the presence of dox, HIV-rtTA does not replicate in the absence of this effector. (C) Dox-controlled replication of HIV-rtTA strains with the original rtTA-2S-S2 gene (left panel) and the F86Y-mutated variant (right panel) in SupT1 T-cells at different dox-concentrations. Virus replication is monitored by measuring the viral capsid protein (CA-p24) in the culture supernatant. Reproduced from [67] (© 2004, the American Society for Biochemistry and Molecular Biology).CC BY-NC · PubMed Central
Fig. (4) Optimization of the Tet-On system through virus evolution. (A) Amino acid substitutions observed in rtTA-2S-S2 (wild-type) upon long-term culturing of HIV-rtTA in human SupT1 T-cells. (B) The transcriptional activity (at 1000 ng/ml dox) and dox-sensitivity of the wild-type, naturally evolved (V1-V10) and constructed (V11-V18) rtTA variants was measured in HeLa X1/6 cells that contain chromosomally integrated copies of the Ptet-luciferase reporter construct. The wild-type rtTA activity at 1000 ng/ml dox was set at 100%. The activity measured at different dox concentrations was used to calculate the dox concentration that each rtTA variant needs to reach an activity comparable to that of the wild-type rtTA at 1000 ng/ml dox. These concentrations are indicated between brackets in the right panel (nd, not determined), and were used to calculate the dox-sensitivity for each rtTA variant (dox-sensitivity of wild-type rtTA set at 1). *, V1-V18 carry the F86Y and A209T mutations in addition to the shown mutations. Reproduced from [69] (© 2006, Zhou et al.).
Fig. (4) Optimization of the Tet-On system through virus evolution. (A) Amino acid substitutions observed in rtTA-2S-S2 (wild-type) upon long-term culturing of HIV-rtTA in human SupT1 T-cells. (B) The transcriptional activity (at 1000 ng/ml dox) and dox-sensitivity of the wild-type, naturally evolved (V1-V10) and constructed (V11-V18) rtTA variants was measured in HeLa X1/6 cells that contain chromosomally integrated copies of the Ptet-luciferase reporter construct. The wild-type rtTA activity at 1000 ng/ml dox was set at 100%. The activity measured at different dox concentrations was used to calculate the dox concentration that each rtTA variant needs to reach an activity comparable to that of the wild-type rtTA at 1000 ng/ml dox. These concentrations are indicated between brackets in the right panel (nd, not determined), and were used to calculate the dox-sensitivity for each rtTA variant (dox-sensitivity of wild-type rtTA set at 1). *, V1-V18 carry the F86Y and A209T mutations in addition to the shown mutations. Reproduced from [69] (© 2006, Zhou et al.).CC BY-NC · PubMed Central
Fig. (5) Comparison of rtTA variants in transiently transfected and stably transduced cells. (A-C) Different human cell lines (HeLa cervix carcinoma and HEK293 embryonal kidney cells) were transfected with low and high amounts of CMV enhancer/promoter-driven PCMV-rtTA (either rtTA2S-M2 [M2], rtTA-V10 or rtTA-V16) and dox-rtTA activated Ptet-luciferase constructs (constructs shown in A), and cultured in the presence of 0 to 1000 ng/ml dox. (B) The luciferase level measured 2 days after transfection reflects the rtTA activity. The activity of M2 at 1000 ng/ml dox was set at 100%. The average of the values obtained for different experimental conditions (different cells and different amounts of DNA) [70] is shown to illustrate the differences between the rtTA variants (no, transfection of cells with the empty vector instead of the rtTA plasmid). The original data for each cell line and amount of DNA are presented in [70]. (C) Fold induction levels, calculated as the ratio between the rtTA activity at the indicated dox concentration and the activity in the absence of dox (0 ng/ml). (D-H) Different human cell lines (SupT1, HeLa, HepG2 hepatocellular carcinoma and SJNB-8 neuroblastoma cells) were transduced with a lentiviral vector containing Ptet-d2EGFP and PCMV-rtTA (M2, V10 or V16) cassettes (construct shown in D). Cells were cultured with dox for 3 days. GFP-positive (GFP+) cells were sorted and cultured without dox for 6 days to switch off GFP expression. The isolated transduced cells were subsequently cultured with different dox concentrations for 3 days, after which the intracellular GFP level was analyzed. (E) The mean fluorescent intensity (MFI) of the total cell population reflects the rtTA activity. The activity of M2 at 1000 ng/ml dox was set at 100%. The average of the values obtained with the different cells (original data published in [70]) is shown to illustrate the differences between the rtTA variants. (F) Fold induction levels, calculated as the ratio between the MFI at the indicated dox concentration and the MFI in the absence of dox (0 ng/ml). (G) The average percentage of GFP+ cells measured for the SupT1, HeLa and SJNB-8 cells that express GFP predominantly in a threshold mode (i.e. increasing the dox concentration activated GFP expression in more cells, rather than that it increased the fluorescence intensity of the GFP+ cells [89]; original data published in [70]). (H) The percentage of GFP+ cells measured for HepG2 cells that express GFP predominantly in a graded mode (i.e. increasing the dox concentration predominantly increased the fluorescence intensity of the GFP+ cells [89]).
Fig. (5) Comparison of rtTA variants in transiently transfected and stably transduced cells. (A-C) Different human cell lines (HeLa cervix carcinoma and HEK293 embryonal kidney cells) were transfected with low and high amounts of CMV enhancer/promoter-driven PCMV-rtTA (either rtTA2S-M2 [M2], rtTA-V10 or rtTA-V16) and dox-rtTA activated Ptet-luciferase constructs (constructs shown in A), and cultured in the presence of 0 to 1000 ng/ml dox. (B) The luciferase level measured 2 days after transfection reflects the rtTA activity. The activity of M2 at 1000 ng/ml dox was set at 100%. The average of the values obtained for different experimental conditions (different cells and different amounts of DNA) [70] is shown to illustrate the differences between the rtTA variants (no, transfection of cells with the empty vector instead of the rtTA plasmid). The original data for each cell line and amount of DNA are presented in [70]. (C) Fold induction levels, calculated as the ratio between the rtTA activity at the indicated dox concentration and the activity in the absence of dox (0 ng/ml). (D-H) Different human cell lines (SupT1, HeLa, HepG2 hepatocellular carcinoma and SJNB-8 neuroblastoma cells) were transduced with a lentiviral vector containing Ptet-d2EGFP and PCMV-rtTA (M2, V10 or V16) cassettes (construct shown in D). Cells were cultured with dox for 3 days. GFP-positive (GFP+) cells were sorted and cultured without dox for 6 days to switch off GFP expression. The isolated transduced cells were subsequently cultured with different dox concentrations for 3 days, after which the intracellular GFP level was analyzed. (E) The mean fluorescent intensity (MFI) of the total cell population reflects the rtTA activity. The activity of M2 at 1000 ng/ml dox was set at 100%. The average of the values obtained with the different cells (original data published in [70]) is shown to illustrate the differences between the rtTA variants. (F) Fold induction levels, calculated as the ratio between the MFI at the indicated dox concentration and the MFI in the absence of dox (0 ng/ml). (G) The average percentage of GFP+ cells measured for the SupT1, HeLa and SJNB-8 cells that express GFP predominantly in a threshold mode (i.e. increasing the dox concentration activated GFP expression in more cells, rather than that it increased the fluorescence intensity of the GFP+ cells [89]; original data published in [70]). (H) The percentage of GFP+ cells measured for HepG2 cells that express GFP predominantly in a graded mode (i.e. increasing the dox concentration predominantly increased the fluorescence intensity of the GFP+ cells [89]).CC BY-NC · PubMed Central
Fig. (6) Identification of the optimal Tet-On system for different applications. Direct comparison of the activity of the rtTA-2S-M2 (M2), rtTA-V10 and rtTA-V16 variants in transiently transfected and stably transduced cells (as shown in Fig. 5) revealed their quality with respect to different parameters. +, good; ++, better; +++, best; n/a, not applicable.
Fig. (6) Identification of the optimal Tet-On system for different applications. Direct comparison of the activity of the rtTA-2S-M2 (M2), rtTA-V10 and rtTA-V16 variants in transiently transfected and stably transduced cells (as shown in Fig. 5) revealed their quality with respect to different parameters. +, good; ++, better; +++, best; n/a, not applicable.CC BY-NC · PubMed Central

Verification

Claims the paper makes

22 Valid · 0 Not valid · 15 Not checked · 21 Own results and interpretations

20 more claims · 2 with their cited sources checked

Create a free account to see all 58 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 31
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 2

Create a free account to see these claims.

Citations

Cites

Show all 89 references

Cited by

See all 434

Metadata

Authors
T. Das, A., Tenenbaum, L., & Berkhout, B.
Venue
Current Gene Therapy
Published
2016-06-16
Volume
16
Issue
3
Pages
156-167
ISSN
1566-5232 (ISSN-L)
OpenAlex
W2398436462
Cited by
434
References
89
Citations by year
2026: 41 · 2025: 58 · 2024: 67 · 2023: 81 · 2022: 57 · 2021: 39 · 2020: 38 · 2019: 22 · 2018: 27 · 2017: 3
FWCI
13.96
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Current Gene Therapy (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • SERVAL (Université de Lausanne) (publishedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • IRIS (submittedVersion)
Funders
Stichting voor de Technische Wetenschappen
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
Keywords
Tet-On system, Tet-off system, doxycycline-inducible expression, gene therapy vectors
MeSH terms
Bacterial Proteins, Carrier Proteins, Doxycycline, Escherichia coli, Gene Expression Regulation, Humans, Operon, Promoter Regions, Genetic, Tetracycline, Transfection, Vaccines, Attenuated, Genetic Therapy, HIV-1, AIDS Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tet-On Systems For Doxycycline-inducible Gene Expression. https://app.cochat.ai/papers/10.2174/1566523216666160524144041
The paper
T. Das, A., Tenenbaum, L., & Berkhout, B. (2016). Tet-On Systems For Doxycycline-inducible Gene Expression. Current Gene Therapy. https://doi.org/10.2174/1566523216666160524144041

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.